电针改善血管认知障碍 没有痴呆症:一项随机临床试验
Ruizhu Lin1, Yaling Dai2, Jianfeng Xu3
1College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China; General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
概括
电针 (EA) 改善了血管认知障碍无痴呆症 (VCIND) 患者的认知功能和大脑连接. 这种治疗增强了默认模式网络活动,与认知改善有积极的相关性.
科学领域:
- 神经科学是一个神经科学.
- 临床医学 临床医学
- 医疗成像医学成像
背景情况:
- 无痴呆症的血管认知障碍 (VCIND) 是一个重大的临床挑战.
- 电针 (EA) 是VCIND的潜在治疗策略.
- 了解EA在VCIND中的机制对于有效治疗至关重要.
研究的目的:
- 研究EA在VCIND患者中的神经成像和认知机制.
- 评估EA对认知功能和大脑活动模式的影响.
主要方法:
- 一项随机试验涉及140名VCIND患者,分为EA和对照组.
- 认知评估包括MoCA,AVLT和Stroop测试.
- 休息状态功能性MRI (fMRI) 用于分析大脑功能连接和灰质体积.
主要成果:
- 在VCIND患者中,EA显著改善了MoCA得分和Stroop测试的性能.
- fMRI显示EA后关键大脑区域的默认模式网络 (DMN) 功能连接性增加.
- 增强的功能连接,特别是在后带带状回环和其他区域之间,与认知功能有积极的相关性.
结论:
- 在VCIND患者中,EA增强了DMN内的功能连接.
- 功能连接性增加与VCIND的认知功能改善有关.
- 在VCIND中,EA显示为改善大脑功能和认知的治疗方法.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120
Electroconvulsive Therapy
31
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
31
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179


